SCM
JSPR icon

Soleus Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Soleus Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-276,312
Closed -$242K – 106
2026
Q1 		$242K Buy
276,312
+76,312
+38% +$106K 0.01% 93
2025
Q4 		$366K Sell
200,000
-1,294,420
-87% -$2.6M 0.01% 89
2025
Q3 		$3.56M Hold
1,494,420
– – 0.18% 65
2025
Q2 		$8.29M Hold
1,494,420
– – 0.55% 43
2025
Q1 		$6.43M Hold
1,494,420
– – 0.46% 47
2024
Q4 		$32M Buy
1,494,420
+150,755
+11% +$3.14M 2.01% 16
2024
Q3 		$25.3M Buy
1,343,665
+67,475
+5% +$1.34M 1.96% 16
2024
Q2 		$29M Buy
1,276,190
+89,094
+8% +$2.14M 2.55% 10
2024
Q1 		$34.9M Buy
1,187,096
+199,998
+20% +$3.55M 2.59% 8
2023
Q4 		$7.79M Buy
987,098
+157,000
+19% +$1.05M 0.86% 37
2023
Q3 		$5.81M Buy
830,098
+52,500
+7% +$641K 0.54% 48
2023
Q2 		$10.7M Buy
777,598
+32,100
+4% +$477K 1.18% 25
2023
Q1 		$13.5M Buy
+745,498
New +$13.8M 1.4% 22

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Soleus Capital Management's JSPR Position: Q2 2026 in Review

Soleus Capital Management sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 276,312 shares — an estimated $242K sold.

Soleus Capital Management first reported a position in JSPR in Q1 2023 and held it in 13 quarters. The position peaked at $34.9M in Q1 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Soleus Capital Management reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Soleus Capital Management sold 276,312 Jasper Therapeutics shares in Q2 2026, an estimated $242K.
  • Soleus Capital Management first reported a position in Jasper Therapeutics in Q1 2023 and held it in 13 quarters.
  • Soleus Capital Management's Jasper Therapeutics position peaked at $34.9M in Q1 2024.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.